Government Endorses NHS Doctors’ AI Commission Recommendations to Revolutionise Healthcare

The government has announced today, 6 October 2026, its decision to accept all 44 recommendations outlined by the National Commission into the Regulation of AI in Healthcare, which were published on 10 September. In conjunction with this announcement, the Medicines and Healthcare products Regulatory Agency (MHRA) is inviting applications for the third phase of AI Airlock, its regulatory sandbox designed for AI-enabled medical devices. This phase will incorporate testing themes that directly reflect the Commission’s recommendations.

Transforming AI Regulation in Healthcare

The Commission has determined that the existing regulatory framework must adapt to accommodate AI technologies, advocating for a more proportionate, lifecycle-based structure. The government’s response signifies a commitment to establishing a pioneering regulatory approach for AI devices in the UK that fosters innovation while ensuring patient safety and maintaining public trust. The reforms are intended to expedite the delivery of safe, effective, and reliable AI solutions to patients, without compromising on essential safeguards as technology progresses.

One of the key recommendations from the Commission was that AI-enabled medical devices should undergo continuous assessment and monitoring throughout their operational lifespan, rather than relying solely on initial evaluations. AI Airlock Phase 3 will implement this principle immediately, collaborating with developers, regulators, and healthcare partners to evaluate how AI devices can be safely overseen and managed post-market. This initiative aims to generate insights, evidence, and solutions that will inform future MHRA guidance and policy. Applications are currently open for developers of qualifying AI-enabled medical devices, with a webinar scheduled for 22 October.

Draft Guidance and New Approaches

Among the initial steps outlined in the government’s response, the MHRA has pledged to publish draft guidance by December 2026 regarding a new strategy for managing modifications to AI-enabled medical devices as they evolve. This shift aims to create a regulatory environment that prioritises safety while allowing timely access to innovative technologies. Furthermore, the MHRA plans to consult on the qualification and classification of AI-enabled devices next year, a key recommendation from the National Commission.

Additional commitments involve investigating new staged authorisation pathways, enabling promising AI tools to be deployed within the NHS under close supervision while further real-world evidence is gathered. A comprehensive implementation roadmap, detailing timelines and responsibilities for all 44 recommendations, is expected to be released by Spring 2027, accompanied by regular progress updates.

Enhancing Patient Engagement and Access

Moreover, the government is dedicated to collaborating with stakeholders across the health system to bolster patient engagement in decision-making processes, improve access to redress when care standards fall short, and ensure equitable distribution of AI benefits across all communities, particularly those underserved.

With the launch of AI Airlock Phase 3 today, the MHRA is inviting applications for its regulatory sandbox, which has received three years of additional government funding following a successful pilot and Phase 2 programme. This phase will concentrate on post-market surveillance and lifecycle regulation, which are central themes of both the Commission’s recommendations and the government’s response.

A Shift Towards Continuous Monitoring

The combined actions of the government’s response and the initiation of AI Airlock Phase 3 signal a transition towards ongoing, real-world monitoring of AI technologies throughout their operational lifespan, rather than relying on a single assessment. In addition, new commitments will ensure that patients are informed when AI is utilised in their care.

Health Innovation Minister James Frith remarked, “We want all patients to benefit from the life-saving potential of AI, with the confidence that it is safe, effective and properly overseen. We also want to see the NHS harness the best new technologies to give patients faster, better care and give staff more time to focus on patients. But innovation must never come at the expense of patient safety.”

Expert Insights on the Regulatory Changes

Chief Executive of the MHRA, Lawrence Tallon, expressed satisfaction with the government’s acceptance of the Commission’s recommendations, stating, “The independent National AI Commission, led by NHS doctors, has presented us with a clear and ambitious blueprint for making the UK the premier destination for safely and swiftly delivering AI products to patients, all while maintaining public trust.”

Professor Alastair Denniston, Chair of the National Commission, voiced his approval of the government’s response. He noted that it demonstrates attentiveness not only to the Commission but also to the insights of over 12,000 patients, clinicians, and members of the public who contributed to the recommendations. “The government’s response confirms its commitment to a people-centred approach to AI that is both safe and efficient,” he added.

Next Steps in Implementation

The newly formed Programme Board will convene to oversee the work already underway within the government, the MHRA, NHS partners, and devolved authorities on the nine priority areas identified in the response. A complete implementation roadmap will be available by Spring 2027, with applications for AI Airlock Phase 3 closing in November 2026 and a webinar for prospective applicants scheduled for 22 October.

Various stakeholders have welcomed the government’s decision to adopt all the recommendations made by the Commission, highlighting the potential for AI to enhance patient care while ensuring robust regulatory frameworks are in place. This approach aims to position the UK as a global leader in AI-enabled healthcare, fostering innovation while prioritising patient safety and public confidence.